2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T429,A total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n = 347), or PRP (n = 342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs -4.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4; P < .001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8; P < .001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm.31:Tae3,CONDOR (Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy) is a large-scale, company-sponsored randomized clinical trial to assess the unique 6-week (loading) and 12-week (maintenance) brolucizumab dosing regimen in proliferative diabetic retinopathy (PDR). To assess the efficacy and safety of brolucizumab, 6 mg, compared with panretinal laser photocoagulation (PRP) in eyes with PDR. CONDOR is a 96-week, 2-arm, single-masked, multicenter, phase 3 randomized clinical trial conducted across 16 countries at 152 sites. Data were analyzed from December 4, 2020 (first participant first visit), to October 30, 2023 (cutoff date). Patients with diabetes and PDR diagnosis and no previous PRP treatment in the study eye were eligible for inclusion. Patients randomized to receive brolucizumab, 6 mg, received 3 loading doses every 6 weeks, followed by every 12 weeks, with the option from week 48 onward to extend the treatment interval by 6 weeks at a time up to 24 weeks based on disease activity. Patients randomized to PRP received treatment in 1 to 4 sessions up to week 12, followed by additional PRP treatment as needed. The primary outcome measure was change from baseline in best-corrected visual acuity (BCVA) at week 54. Secondary outcomes included change in DR progression, prevention of center-involved diabetic macular edema, change in Diabetic Retinopathy Severity Score levels, and safety. A total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n = 347), or PRP (n = 342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs -4.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4; P < .001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8; P < .001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm. In the CONDOR randomized clinical trial, brolucizumab was superior to PRP in preserving visual acuity and may be a viable treatment alternative to PRP monotherapy for patients with PDR. ClinicalTrials.gov Identifier: NCT04278417.32:T119e, Importance CONDOR (Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy) is a large-scale, company-sponsored randomized clinical trial to assess the unique 6-week (loading) and 12-week (maintenance) brolucizumab dosing regimen in proliferative diabetic retinopathy (PDR). Objective To assess the efficacy and safety of brolucizumab, 6 mg, compared with panretinal laser photocoagulation (PRP) in eyes with PDR. Design, Setting, and Participants CONDOR is a 96-week, 2-arm, single-masked, multicenter, phase 3 randomized clinical trial conducted across 16 countries at 152 sites. Data were analyzed from December 4, 2020 (first participant first visit), to October 30, 2023 (cutoff date). Patients with diabetes and PDR diagnosis and no previous PRP treatment in the study eye were eligible for inclusion. Intervention Patients randomized to receive brolucizumab, 6 mg, received 3 loading doses every 6 weeks, followed by every 12 weeks, with the option from week 48 onward to extend the treatment interval by 6 weeks at a time up to 24 weeks based on disease activity. Patients randomized to PRP received treatment in 1 to 4 sessions up to week 12, followed by additional PRP treatment as needed. Main Outcomes and Measures The primary outcome measure was change from baseline in best-corrected visual acuity (BCVA) at week 54. Secondary outcomes included change in DR progression, prevention of center-involved diabetic macular edema, change in Diabetic Retinopathy Severity Score levels, and safety. Results A total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n = 347), or PRP (n = 342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs −4.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4; P &lt; .001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8; P &lt; .001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm. Conclusions and Relevance In the CONDOR randomized clinical trial, brolucizumab was superior to PRP in preserving visual acuity and may be a viable treatment alternative to PRP monotherapy for patients with PDR. Trial Registration ClinicalTrials.gov Identifier: NCT04278417 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Proliferative Diabetic Retinopathy: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Proliferative Diabetic Retinopathy (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Proliferative%20Diabetic%20Retinopathy\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Proliferative Diabetic Retinopathy\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Proliferative%20Diabetic%20Retinopathy\"}]}}"}}]],["$","$L2f",null,{"title":"Proliferative Diabetic Retinopathy: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Proliferative Diabetic Retinopathy with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1186/s12886-026-05199-5","pmid":"42638100","title":"Sympathetic ophthalmia complicating proliferative diabetic retinopathy: diagnostic and therapeutic challenges during pregnancy","journal_title":"BMC Ophthalmology","journal_issn":"1471-2415","published_at":"2026-08-24T00:00:00.000Z","url":"https://doi.org/10.1186/s12886-026-05199-5","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-02T06:22:41.110Z","updated_at":"2026-09-02T06:22:41.110Z","tags":[{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"condition","value":"Proliferative Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"condition","value":"Sympathetic Ophthalmia","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"condition","value":"Type 1 Diabetes Mellitus","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"condition","value":"Uveitis","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"generic","value":"methylprednisolone","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"generic","value":"prednisolone","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"Corticosteroid","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"Panretinal Photocoagulation","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"Pars Plana Vitrectomy","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"warning","value":"Adalimumab continuation into the third trimester was individualized given monocular status; this deviates from some guideline recommendations and should not be applied routinely.","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"warning","value":"Multiple confounding factors (SO, PDR, poor glycemic control, two pregnancies) coexist, making causal attribution of outcomes to any single intervention uncertain.","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"warning","value":"The Humira brand tag is inferred from adalimumab use; the paper does not specify the brand name explicitly.","value_numeric":null},{"paper_doi":"10.1186/s12886-026-05199-5","tag_type":"warning","value":"This is a single case report (n=1); findings should not be generalized to broader clinical practice without corroborating evidence.","value_numeric":null}],"summaries":{"what_studied":"A single case of a 27-year-old woman with poorly controlled type 1 diabetes who developed sympathetic ophthalmia (SO) in the fellow eye 10 weeks after penetrating ocular injury repair, with coexisting proliferative diabetic retinopathy (PDR) and a concurrent second pregnancy, managed with IV methylprednisolone, oral prednisolone taper, adalimumab, augmented panretinal photocoagulation (PRP), and postpartum pars plana vitrectomy.","key_result":"Visual acuity improved from 20/100 to 20/25 after systemic immunosuppression and augmented PRP, with partial regression of neovascularization; following postpartum vitrectomy for recurrent vitreous hemorrhage and tractional retinal detachment, final VA was 20/40 with inactive uveitis and a flat, attached retina.","limitations":"Single case report limits generalizability; multiple overlapping variables (SO, PDR, two pregnancies, poor glycemic control) make it impossible to isolate the contribution of each factor; no control or comparator eye with similar combined pathology.","practice_takeaway":"When SO is diagnosed in a patient with PDR, prompt systemic immunosuppression can itself reduce neovascular activity—consider early adalimumab as a steroid-sparing agent to limit corticosteroid-induced hyperglycemia. In pregnant patients, defer intravitreal anti-VEGF when possible, favor PRP, individualize biologic continuation with multidisciplinary input, and plan vitrectomy for the postpartum period unless vision-threatening urgency demands earlier intervention."}},{"doi":"10.1016/j.ophtha.2026.07.029","pmid":"42546975","title":"Systemic Interleukin-6 Inhibition and Risk of Diabetic Retinopathy Development and Progression","journal_title":"Ophthalmology","journal_issn":"0161-6420","published_at":"2026-08-03T00:00:00.000Z","url":"https://doi.org/10.1016/j.ophtha.2026.07.029","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-13T13:22:54.301Z","updated_at":"2026-08-13T13:22:54.301Z","tags":[{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"condition","value":"Diabetes Mellitus","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"condition","value":"Diabetic Macular Edema","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"condition","value":"Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"condition","value":"Proliferative Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"modality","value":"IL-6 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"sample_size","value":"n=5210","value_numeric":5210},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"warning","value":"No specific IL-6 inhibitor agents (e.g., tocilizumab, sarilumab, siltuximab) are named or broken out in the abstract; drug-level effects are indeterminate from available text.","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously — the authors themselves call for prospective trials before clinical translation; clinicians should interpret findings as hypothesis-generating.","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"warning","value":"The primary sample size (n=5,210) reflects the primary propensity-matched cohort; the secondary NPDR analysis used a smaller matched cohort of 2,114 (1,057 per group).","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.07.029","tag_type":"warning","value":"The study publication date (2026-08-03) is recent; peer review status and any post-publication commentary are unknown at this time.","value_numeric":null}],"summaries":{"what_studied":"This retrospective propensity score-matched cohort study evaluated whether systemic IL-6 inhibitor use reduces the risk of incident diabetic retinopathy (DR), DR progression, vision-threatening complications, and retinal interventions in adults with type 1 or type 2 diabetes, using the US TriNetX EHR network (2004–2026) with up to 5-year follow-up.","key_result":"IL-6 inhibitor use was associated with significantly lower 5-year risks of NPDR (RR 0.50), PDR (RR 0.47), DME (RR 0.37), and vitreous hemorrhage (RR 0.41) vs. matched controls; anti-VEGF, PRP, and PPV rates were also lower; no significant difference was seen for neovascular glaucoma.","limitations":"Retrospective EHR-based design limits causal inference; residual confounding from unmeasured variables (e.g., glycemic control trends, disease severity) is possible; DR outcomes rely on diagnostic coding accuracy rather than standardized ophthalmic grading.","practice_takeaway":"Systemic IL-6 inhibitors in diabetic patients may offer a protective effect against DR onset and progression, but prospective trials are needed before incorporating IL-6 pathway modulation into routine diabetic eye disease management."}},{"doi":"10.1097/iae.0000000000004904","pmid":"42262504","title":"Diabetic Retinopathy Outcomes Among Unhoused Individuals: A Big Data Analysis","journal_title":"Retina","journal_issn":"0275-004X","published_at":"2026-06-09T00:00:00.000Z","url":"https://doi.org/10.1097/iae.0000000000004904","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-13T15:34:53.845Z","updated_at":"2026-06-13T15:34:53.845Z","tags":[{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"condition","value":"Diabetic Macular Edema","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"condition","value":"Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"condition","value":"Proliferative Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"condition","value":"Tractional Retinal Detachment","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"condition","value":"Type 1 Diabetes","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"condition","value":"Type 2 Diabetes","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"condition","value":"Vitreous Hemorrhage","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"sample_size","value":"n=1190152","value_numeric":1190152},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"warning","value":"Sample size of 1,190,152 reflects the total unhoused + housed cohort at baseline; the propensity-matched cohort was 2,911 per group (5,822 total).","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"warning","value":"Study design labeled as retrospective cohort based on EHR network methodology described; the paper does not explicitly use this label.","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004904","tag_type":"warning","value":"The full text retrieved was a Lippincott author permissions page, not the study manuscript; all structured data were extracted solely from the abstract and results sections provided.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated diabetic retinopathy (DR) severity, vision-threatening complications, treatment patterns, and longitudinal outcomes in unhoused vs. stably housed patients with type 1 or 2 diabetes using a large multicenter EHR network (9,643 unhoused; 1,180,509 housed), with a propensity score-matched cohort (n=2,911 per group) for 1-year incident outcomes.","key_result":"Unhoused patients presented with far higher rates of PDR (5.24% vs. 1.46%), vitreous hemorrhage (4.04% vs. 1.03%), and tractional retinal detachment (1.34% vs. 0.24%); in matched analysis, unhoused status raised 1-year risk of DME (HR 1.28), PDR (HR 1.25), and vitreous hemorrhage (HR 1.35), and independently predicted PDR (HR 1.55; 95% CI 1.41–1.71) after adjusting for other social determinants of health.","limitations":"- ICD-10 coding for unhoused status may undercount true housing instability, introducing misclassification bias.\n- Only 30.3% of unhoused patients achieved ≥6 months of follow-up vs. 55.2% of housed patients, so matched analyses likely underrepresent the most disengaged patients.\n- Retrospective EHR design cannot establish causality or fully account for unmeasured confounders.","practice_takeaway":"Clinicians should treat unhoused status as a high-risk flag for advanced DR and prioritize aggressive, low-barrier screening at first contact, since these patients are unlikely to return for follow-up. Socially informed care pathways — such as same-day treatment and community outreach — are needed to close the gap in outcomes."}},{"doi":"10.1016/j.ajo.2026.05.042","pmid":"42219076","title":"Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis","journal_title":"American Journal of Ophthalmology","journal_issn":"0002-9394","published_at":"2026-06-01T00:00:00.000Z","url":"https://doi.org/10.1016/j.ajo.2026.05.042","source_score":3,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:07.612Z","updated_at":"2026-06-10T14:24:07.612Z","tags":[{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"condition","value":"Diabetic Macular Edema","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"condition","value":"Macular Edema from Retinal Vein Occlusion","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"condition","value":"Myopic Choroidal Neovascularization","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"condition","value":"Neovascular Age-Related Macular Degeneration","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"condition","value":"Proliferative Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"condition","value":"Retinal Detachment","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"modality","value":"Anti-VEGF Agent","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"sample_size","value":"n=834814","value_numeric":834814},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"warning","value":"Level of evidence assigned as 3 (systematic review of observational/non-randomized studies) because all included studies were non-randomized and the authors explicitly rated overall certainty as 'low.' This is not a level-1 RCT-based meta-analysis.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"warning","value":"Per-eye risk estimate (0.08%) carries high heterogeneity (I²=66.7%) and wide confidence intervals; clinical use of this figure should acknowledge substantial uncertainty.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"warning","value":"The 'practice_changing' impact flag is applied cautiously: while RD risk is rare, providing a precise pooled estimate meaningfully improves informed consent discussions where no prior consensus figure existed.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.05.042","tag_type":"warning","value":"Tractional RD risk in severe PDR (3.6%) is derived from a single study and may not generalize broadly to all PDR patients receiving anti-VEGF.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and meta-analysis (PRISMA/PROSPERO) pooled the risk of retinal detachment (RD) after intravitreal anti-VEGF injection across 12 studies (834,814 injections) in patients treated for nAMD, diabetic macular edema, macular edema from retinal vein occlusion, proliferative diabetic retinopathy, or myopic choroidal neovascularization.","key_result":"Pooled rhegmatogenous RD (RRD) risk was **0.012%** per injection (1 in 8,675; 95% CI 0.009–0.015%, I²=14.4%); per-eye risk was **0.08%** (1 in 1,250; 95% CI 0.02–0.31%, I²=66.7%). Subgroup analyses found no significant differences by indication, setting, provider type, or injection volume. Tractional RD in severe PDR was notably higher at **3.6%** (1 in 28 injections).","limitations":"- Evidence rated **low certainty**; most contributing studies lacked eye-level denominators, leading to wider uncertainty in per-eye estimates.\n- The pooled mean of 13.8 injections/eye likely **underestimates** real-world cumulative exposure, so lifetime per-eye risk is probably higher.\n- Inconsistent reporting of RD subtypes, ocular comorbidities, and injection technique prevents risk stratification.","practice_takeaway":"Clinicians can reassure most patients that RRD after anti-VEGF injection is rare (~1 in 8,675 injections; ~1 in 1,250 eyes), making this a quantifiable anchor for informed consent discussions. Patients with severe proliferative diabetic retinopathy warrant special counseling given a substantially higher tractional RD risk (~1 in 28 injections)."}},{"doi":"10.1001/jamaophthalmol.2026.1008","pmid":"42024409","title":"Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy","journal_title":"JAMA Ophthalmology","journal_issn":"2168-6165","published_at":"2026-04-23T00:00:00.000Z","url":"https://doi.org/10.1001/jamaophthalmol.2026.1008","source_score":21,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-24","doi":"10.1001/jamaophthalmol.2026.1008","days":"30","issn":"2168-6165","rank":"7","field":"Clinical Medicine","score":"21","category":"Ophthalmology","categories":["Ophthalmology"],"_categories":["Ophthalmology"]},"pubmed":{"doi":"10.1001/jamaophthalmol.2026.1008","title":"Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.","journal":"JAMA ophthalmology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"42024409","conclusions":"","publication_date":"2026-04-23T00:00:00"},"crossref":{"DOI":"10.1001/jamaophthalmol.2026.1008","URL":"https://doi.org/10.1001/jamaophthalmol.2026.1008","ISSN":["2168-6165"],"link":[{"URL":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2847704/jamaophthalmology_wolf_2026_oi_260018_1775569472.28639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy"],"author":[{"given":"Sebastian","family":"Wolf","sequence":"first","affiliation":[{"name":"Bern Photographic Reading Center, Department of Ophthalmology, University Hospital, University of Bern, Bern, Switzerland"}]},{"given":"Youxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Beijing, China"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Medical University, Tianjin, China"}]},{"given":"Masahiko","family":"Shimura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Bellaire"},{"name":"Retina Consultants of America, Houston, Texas"}]},{"given":"Andres","family":"Emanuelli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico"}]},{"given":"Hani","family":"Salehi-Had","sequence":"additional","affiliation":[{"name":"Retina Associates of Southern California, Huntington Beach"}]},{"given":"Kang","family":"Yan","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for BioMedical Research Co Ltd, Shanghai, China"}]},{"given":"Lidija","family":"Kovacic","sequence":"additional","affiliation":[{"name":"Novartis AG, Basel, Switzerland"}]},{"given":"Yongsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Novartis AG, Basel, Switzerland"}]}],"issued":{"date-parts":[[2026,4,23]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-04-23T15:30:36Z","timestamp":1776958236000,"date-parts":[[2026,4,23]]},"indexed":{"date-time":"2026-04-23T15:47:56Z","timestamp":1776959276483,"date-parts":[[2026,4,23]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2847704"}},"subtitle":["The CONDOR Randomized Clinical Trial"],"deposited":{"date-time":"2026-04-23T15:30:37Z","timestamp":1776958237000,"date-parts":[[2026,4,23]]},"issn-type":[{"type":"print","value":"2168-6165"}],"published":{"date-parts":[[2026,4,23]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.3390/life13051098","key":"eoi260018r1","year":"2023","issue":"5","author":"Bahr","volume":"13","first-page":"1098","unstructured":null,"article-title":"Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy.","journal-title":"Life (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2021.04.027","key":"eoi260018r2","year":"2021","issue":"11","author":"Teo","volume":"128","first-page":"1580","unstructured":null,"article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMct0908432","key":"eoi260018r3","year":"2011","issue":"16","author":"Bressler","volume":"365","first-page":"1520","unstructured":null,"article-title":"Panretinal photocoagulation for proliferative diabetic retinopathy.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1080/08820538.2017.1353820","key":"eoi260018r4","year":"2018","issue":"1","author":"Reddy","volume":"33","first-page":"83","unstructured":null,"article-title":"Panretinal photocoagulation: a review of complications.","journal-title":"Semin Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajo.2005.02.029","key":"eoi260018r5","year":"2005","issue":"1","author":"Shimura","volume":"140","first-page":"8","unstructured":null,"article-title":"Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision.","journal-title":"Am J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2018.04.039","key":"eoi260018r6","year":"2018","issue":"11","author":"Bressler","volume":"125","first-page":"1776","unstructured":null,"article-title":"Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: factors associated with vision and edema outcomes.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaophthalmol.2018.3255","key":"eoi260018r7","year":"2018","issue":"10","author":"Gross","volume":"136","first-page":"1138","unstructured":null,"article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","journal-title":"JAMA Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.3389/fendo.2023.1144422","key":"eoi260018r8","year":"2023","issue":null,"author":"Xie","volume":"14","first-page":null,"unstructured":null,"article-title":"Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis.","journal-title":"Front Endocrinol (Lausanne)","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)31193-5","key":"eoi260018r9","year":"2017","issue":"10085","author":"Sivaprasad","volume":"389","first-page":"2193","unstructured":null,"article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2018.08.001","key":"eoi260018r10","year":"2019","issue":"1","author":"Sun","volume":"126","first-page":"87","unstructured":null,"article-title":"Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2019.12.031","key":"eoi260018r11","year":"2020","issue":"7","author":"Nguyen","volume":"127","first-page":"963","unstructured":null,"article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41433-020-0961-6","key":"eoi260018r12","year":"2020","issue":null,"author":"Amoaku","volume":"34","first-page":"1","unstructured":null,"article-title":"Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.","journal-title":"Eye (Lond)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajo.2022.01.004","key":"eoi260018r13","year":"2022","issue":null,"author":"Brown","volume":"238","first-page":"157","unstructured":null,"article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema.","journal-title":"Am J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2015.15217","key":"eoi260018r14","year":"2015","issue":"20","author":"Gross","volume":"314","first-page":"2137","unstructured":null,"article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1097/MD.0000000000034856","key":"eoi260018r15","year":"2023","issue":"39","author":"Fu","volume":"102","first-page":null,"unstructured":null,"article-title":"Efficacy and safety of pan retinal photocoagulation combined with intravitreal anti-VEGF agents for high-risk proliferative diabetic retinopathy: a systematic review and meta-analysis.","journal-title":"Medicine (Baltimore)","doi-asserted-by":"publisher"},{"DOI":"10.1097/ICU.0000000000000799","key":"eoi260018r16","year":"2021","issue":"6","author":"Nanegrungsunk","volume":"32","first-page":"590","unstructured":null,"article-title":"Prevention of vision-threatening complications in diabetic retinopathy: two perspectives based on results from the DRCR Retina Network Protocol W and the Regeneron-sponsored PANORAMA.","journal-title":"Curr Opin Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2016.12.005","key":"eoi260018r17","year":"2017","issue":"4","author":"Bressler","volume":"124","first-page":"431","unstructured":null,"article-title":"Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1080/08820538.2023.2271095","key":"eoi260018r18","year":"2024","issue":"4","author":"Abu Serhan","volume":"39","first-page":"251","unstructured":null,"article-title":"Safety and efficacy of brolucizumab in the treatment of diabetic macular edema and diabetic retinopathy: a systematic review and meta-analysis.","journal-title":"Semin Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaophthalmol.2023.5248","key":"eoi260018r19","year":"2023","issue":"12","author":"Singh","volume":"141","first-page":"1152","unstructured":null,"article-title":"Efficacy and safety of brolucizumab for diabetic macular edema: the KINGFISHER randomized clinical trial.","journal-title":"JAMA Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2011.12.039","key":"eoi260018r20","year":"2012","issue":"4","author":"Nguyen","volume":"119","first-page":"789","unstructured":null,"article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaophthalmol.2021.2809","key":"eoi260018r21","year":"2021","issue":"9","author":"Brown","volume":"139","first-page":"946","unstructured":null,"article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial.","journal-title":"JAMA Ophthalmol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Ophthalmology"],"reference-count":21,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,23]]},"references-count":21,"short-container-title":["JAMA Ophthalmol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamaophthalmol.2026.1008","is_oa":true,"title":"Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy","updated":"2026-04-27T08:42:52+00:00","published_date":"2026-04-23","best_oa_location":{"url":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2847704/jamaophthalmology_wolf_2026_oi_260018_1775569472.28639.pdf","pmh_id":null,"url_for_pdf":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2847704/jamaophthalmology_wolf_2026_oi_260018_1775569472.28639.pdf","url_for_landing_page":"https://doi.org/10.1001/jamaophthalmol.2026.1008"}}},"created_at":"2026-05-07T22:49:15.666Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"brand","value":"Beovu","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"condition","value":"Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"condition","value":"Proliferative Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"generic","value":"brolucizumab","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"sample_size","value":"n=689","value_numeric":689},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"warning","value":"Brand name 'Beovu' used for brolucizumab; confirm regulatory approval status for PDR indication in relevant jurisdiction before clinical use.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"warning","value":"Single-masked design (investigator-masked, not patient-masked) limits blinding rigor for subjective endpoints like BCVA.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"warning","value":"The article DOI references a 2026 publication date, which is ahead of conventional indexing; results should be verified upon formal publication.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1008","tag_type":"warning","value":"The trial is company-sponsored, which may introduce bias in outcomes reporting or design choices.","value_numeric":null}],"summaries":{"what_studied":"The CONDOR phase 3 RCT compared intravitreal brolucizumab 6 mg (loading every 6 weeks × 3, then every 12 weeks, with optional extension to 24 weeks) vs. panretinal photocoagulation (PRP) in 689 treatment-naive PDR patients across 152 sites in 16 countries over 96 weeks, with the primary endpoint at week 54.","key_result":"Brolucizumab was superior to PRP for BCVA change at week 54 (+0.2 vs. −4.2 letters; difference 4.4 letters, 95% CI 2.4–6.4; P < .001). PDR resolution occurred in 63.6% of brolucizumab patients vs. 22.4% of PRP patients. However, intraocular inflammation (including retinal vasculitis) occurred in 5.2% of brolucizumab patients vs. 0.6% with PRP.","limitations":"- Single-masked design (patients could not be blinded to treatment arm), which may introduce bias in subjective outcomes.\n- Company-sponsored trial raises potential for industry bias.\n- 96-week trial data beyond week 54 (the primary endpoint cutoff) are not yet fully reported here.","practice_takeaway":"Brolucizumab preserves vision better than PRP monotherapy in PDR, but clinicians should counsel patients on a meaningful intraocular inflammation risk (~5%), including retinal vasculitis, before choosing it over laser. It may be a viable PRP alternative, particularly for patients at risk of vision loss from laser-related side effects."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Proliferative Diabetic Retinopathy"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Proliferative Diabetic Retinopathy"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Proliferative Diabetic Retinopathy"}}}]]

Papers